Renee Lucander

CEO at Calliditas Therapeutics

Speaker

Renée Aguiar-Lucander has over 30 years of experience in company management, strategic and financial development of US and European private and public companies with core sector expertise in healthcare and technology. Renée joined Calliditas in 2017 as CEO and has taken the Company from its initial listing on the Swedish stock exchange in 2018 – in what was one of the largest European IPOs that year - to a successful listing on US NASDAQ in June 2020 raising $90 million and subsequently building a commercial biopharma company focused on rare disease. Calliditas was the first company globally to successfully complete a Phase 3 study in the rare autoimmune disease of IgA Nephropathy, and to bring the first ever approved drug to market.

Before joining Calliditas, Renée Aguiar-Lucander was a Partner and COO of Omega Fund Management, an international venture capital company focused on investments within the life science sector. Before that, she served as a Partner in the venture capital group 3i Group plc in London, where she managed the publicly quoted assets and was co-head of the global healthcare and technology portfolio. Prior to this, Renée Aguiar-Lucander was a European Group Head and Managing Director at a global investment bank and has more than 12 years’ experience in corporate finance. Prior to her career in investment banking, she was the Head of European Sales and Marketing in a company focused on the sale of analytical software for financial services.